相似文献
1
The ethics of CYP2D6 testing for patients considering tamoxifen.
Breast Cancer Res. 2007;9(2):103. doi: 10.1186/bcr1663.
2
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.
3
CYP2D6 genotype and tamoxifen response.
Breast Cancer Res. 2005 Jul 29;7(5):E6. doi: 10.1186/bcr1297.
4
CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
Clin Adv Hematol Oncol. 2008 Jul;6(7):493-4.
5
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Curr Med Res Opin. 2010 Nov;26(11):2535-42. doi: 10.1185/03007995.2010.518304. Epub 2010 Sep 17.
6
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24.
7
CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ. 2008 May;23(1):1-4.
8
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Breast Cancer Res. 2007;9(1):R7. doi: 10.1186/bcr1640.
9
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.
10
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
Breast Cancer Res Treat. 2010 Jan;119(1):33-8. doi: 10.1007/s10549-009-0328-y. Epub 2009 Feb 3.
本文引用的文献
1
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18.
2
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
J Natl Cancer Inst. 2005 Jan 5;97(1):30-9. doi: 10.1093/jnci/dji005.
3
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15.
4
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. doi: 10.1093/jnci/djg108.
Zotero 插件